Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Vanicream- ActiveDrug: Vanicream- Dupilumab-naïve
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 433
- Registration Number
- NCT05436535
- Locations
- 🇺🇸
University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California, United States
🇺🇸University of Pennsylvania, Perelman Center for Advanced Medicine: Department of Dermatology, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles: Division of Clinical Immunology & Allergy, Los Angeles, California, United States
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
- Conditions
- HIV
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-05-18
- Target Recruit Count
- 48
- Registration Number
- NCT05406583
- Locations
- 🇺🇸
University of Colorado Denver NICHD CRS, Aurora, Colorado, United States
🇺🇸Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States
🇺🇸Rush University, Cook County Hospital NICHD CRS, Chicago, Illinois, United States
Anti-malaria MAb in Kenyan Children
- Conditions
- Plasmodium Falciparum InfectionMalaria
- Interventions
- Other: Normal Saline
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-04-16
- Target Recruit Count
- 720
- Registration Number
- NCT05400655
- Locations
- 🇰🇪
Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR), Kisumu, Kenya
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
- Conditions
- Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 70
- Registration Number
- NCT05398809
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
- Conditions
- Nipah Virus Infection
- Interventions
- Biological: mRNA -1215
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 50
- Registration Number
- NCT05398796
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
- Conditions
- Tuberculous Meningitis
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 330
- Registration Number
- NCT05383742
- Locations
- 🇵🇪
Socios en Salud Sucursal Peru CRS (Site ID: 31985), Lima, Peru
🇵🇪Barranco CRS (Site ID:11301), Lima, Peru
🇵🇭TB HIV Innovations and Clinical Research Foundation Corp (Site ID: 31981), Cavite, Philippines
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-02-20
- Target Recruit Count
- 240
- Registration Number
- NCT05347771
- Locations
- 🇺🇸
Children's Hospital Colorado: Allergy Program, Aurora, Colorado, United States
🇺🇸Children's National Medical Center: Children's Research Institute, Washington, District of Columbia, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology, Chicago, Illinois, United States
Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis
- Conditions
- Chronic Granulomatous Disease-associated Colitis
- Interventions
- Drug: MTP 101-LF
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 20
- Registration Number
- NCT05333471
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CD40L Antagonism in Rheumatoid Arthritis (RA)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo for VIB4920Drug: VIB4920 with TNFiDrug: VIB4920 without TNFi
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-24
- Target Recruit Count
- 104
- Registration Number
- NCT05306353
- Locations
- 🇺🇸
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco, California, United States
🇺🇸University of Colorado School of Medicine: Division of Rheumatology, Aurora, Colorado, United States
🇺🇸Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology, Boston, Massachusetts, United States
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo for Voclosporin
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 120
- Registration Number
- NCT05306873
- Locations
- 🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, United States
🇺🇸Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States